Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Transplacental immune modulation with a bacterial-derived agent protects against allergic airway inflammation
Kyle T. Mincham, … , Patrick G. Holt, Deborah H. Strickland
Kyle T. Mincham, … , Patrick G. Holt, Deborah H. Strickland
Published August 28, 2018
Citation Information: J Clin Invest. 2018;128(11):4856-4869. https://doi.org/10.1172/JCI122631.
View: Text | PDF
Research Article Cell biology Immunology

Transplacental immune modulation with a bacterial-derived agent protects against allergic airway inflammation

  • Text
  • PDF
Abstract

Chronic allergic inflammatory diseases are a major cause of morbidity, with allergic asthma alone affecting over 300 million people worldwide. Epidemiological studies demonstrate that environmental stimuli are associated with either the promotion or prevention of disease. Major reductions in asthma prevalence are documented in European and US farming communities. Protection is associated with exposure of mothers during pregnancy to microbial breakdown products present in farm dusts and unprocessed foods and enhancement of innate immune competence in the children. We sought to develop a scientific rationale for progressing these findings toward clinical application for primary disease prevention. Treatment of pregnant mice with a defined, clinically approved immune modulator was shown to markedly reduce susceptibility of their offspring to development of the hallmark clinical features of allergic airway inflammatory disease. Mechanistically, offspring displayed enhanced dendritic cell–dependent airway mucosal immune surveillance function, which resulted in more efficient generation of mucosal-homing regulatory T cells in response to local inflammatory challenge. We provide evidence that the principal target for maternal treatment effects was the fetal dendritic cell progenitor compartment, equipping the offspring for accelerated functional maturation of the airway mucosal dendritic cell network following birth. These data provide proof of concept supporting the rationale for developing transplacental immune reprogramming approaches for primary disease prevention.

Authors

Kyle T. Mincham, Naomi M. Scott, Jean-Francois Lauzon-Joset, Jonatan Leffler, Alexander N. Larcombe, Philip A. Stumbles, Sarah A. Robertson, Christian Pasquali, Patrick G. Holt, Deborah H. Strickland

×

Figure 1

Response in early life sensitizes mice to aeroallergen challenge.

Options: View larger image (or click on image) Download as PowerPoint
Response in early life sensitizes mice to aeroallergen challenge.
(A) Se...
(A) Serum titers of OVA-specific IgE as measured by in vivo passive cutaneous anaphylaxis assay. (B) Absolute numbers of macrophages (Mϕ), eosinophils (Eos), neutrophils (Neut), and lymphocytes (Lymph) as determined by bronchoalveolar lavage (BAL) 24 hours after challenge. (C) Airway hyperresponsiveness to MCh challenge using 30 mg/ml MCh. (D–F) Analysis of CD3+CD4+CD25+FoxP3– effector T cells (Teffs) within airway tissues (ADLNs, trachea, and peripheral lung) showing (D) Teffs as a proportion of CD4+ T cells, (E) mean fluorescence intensity (MFI) of CD25 on Teffs, and (F) the proportion of Ki67+ Teffs. (G–I) Analysis of CD3+CD4+CD25+FoxP3+ Tregs within airway tissues showing (G) Tregs as a proportion of total CD4+ T cells, (H) MFI of CD25 on Tregs, and (I) the proportion of Ki67+ Tregs. (J) IAIE+F4/80–CD11c+ cDCs and (K) IAIE+Ly6G/Clo/+F4/80–CD11c+CD11b–B220+ pDCs as a proportion of total CD45+ leukocytes in airway tissue samples. (L and M) Absolute numbers of (L) CD11b+ and (M) CD103+ cDCs within airway tissue samples. (N–P) MFI of IAIE expression on (N) CD11b+ cDCs, (O) CD103+ cDCs, and (P) pDCs within airway tissue samples. (Q) Proportion of inflammatory DCs within airway tissue samples. Data are presented from individual animals comparing naive controls (white) versus OVA-sensitized and aerosol-challenged offspring (with sample collection 24 hours after challenge; red) and displayed as box-and-whisker plots showing median, first quartile (Q1), and third quartile (Q3) and minimum to maximum values of n ≥6 independent experiments. #Total peripheral lung cells data are displayed as cells per milligram of tissue (L and M). Statistical significance was determined using Student’s t test or Mann-Whitney U test (A, B, and E–Q) or 2-way ANOVA followed by Sidak’s multiple comparisons test (C) and is presented as *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Raw, airway resistance.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts